Synergistic effects of anti-CTLA-4 antibodies are demonstrated in combination with vaccines in EL4 lymphoma [26], B16 melanoma [27], prostate cancer [28] and SM1 mammary carcinoma [29] models suggesting that combination immunotherapy activates the immune system, sustains a functional response and reverses tumor tolerance. The gene discussed is CTLA4; the disease is melanoma.